Form 8-K - Current report:
SEC Accession No. 0001558370-23-002835
Filing Date
2023-03-06
Accepted
2023-03-06 07:15:40
Documents
14
Period of Report
2023-03-06
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K acrs-20230306x8k.htm   iXBRL 8-K 39370
2 EX-99.1 acrs-20230306xex99d1.htm EX-99.1 17881
3 GRAPHIC acrs-20230306xex99d1001.jpg GRAPHIC 8905
  Complete submission text file 0001558370-23-002835.txt   195136

Data Files

Seq Description Document Type Size
4 EX-101.SCH acrs-20230306.xsd EX-101.SCH 3052
5 EX-101.LAB acrs-20230306_lab.xml EX-101.LAB 16010
6 EX-101.PRE acrs-20230306_pre.xml EX-101.PRE 10317
8 EXTRACTED XBRL INSTANCE DOCUMENT acrs-20230306x8k_htm.xml XML 4794
Mailing Address 640 LEE ROAD SUITE 200 WAYNE PA 19087
Business Address 640 LEE ROAD SUITE 200 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

EIN.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37581 | Film No.: 23707543
SIC: 2834 Pharmaceutical Preparations